Are Synthetic Cannabinoids (K2 / Spice) legal in Malaysia?

Legal status

Controlled only where a compound is named in the lists of the Dangerous Drugs Act 1952 or the Poisons Act 1952. The synthetic cannabinoids are named compound by compound and they are split across both Acts, because Malaysia has no generic synthetic cannabinoid clause: the Dangerous Drugs Act 1952 contains no analogue provision at all. Part III of its First Schedule names about a dozen of them, among them the indazole carboxamides sold as ADB-CHMINACA, as ADB-FUBINACA, as AB-CHMINACA and as AB-PINACA, together with CUMYL-4CN-BINACA, with MDMB-4en-PINACA, with 5F-ADB, with FUB-AMB, with UR-144, with CUMYL-PEGACLONE and with 5F-PB-22. The Poisons Act 1952 Third Schedule names a different set, among them JWH-018, and AM-2201, and XLR-11, and MDMB-CHMICA, and 5F-APINACA, and 5F-AMB. So whether a given synthetic cannabinoid is capital-eligible depends on which one it is, and a new one that is in neither list is, on the text, in neither regime until the Minister adds it.

Consequences if caught

Section 39B(2) reaches the synthetic cannabinoids that Part III names, and only those. There is no class entry and the Dangerous Drugs Act contains no analogue provision at all, measured across the whole Act, so this cell cannot answer for a compound by family. Part III names about a dozen of them individually, among them the indazole carboxamide printed as «N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA, MAB-CHMINACA)», and the compounds sold as ADB-FUBINACA, as AB-CHMINACA, as AB-PINACA, as CUMYL-4CN-BINACA, as MDMB-4en-PINACA, as 5F-ADB, as FUB-AMB, as the «(1-Pentyl-1H-indol-3-yl)(2,2,3,3 tetramethylcyclopropyl) methanone (UR-144)» of that Part, as CUMYL-PEGACLONE and as 5F-PB-22. For any of those, the sentence is death or imprisonment for life. The chain is short and it passes through no weight at any point. Section 2 defines a «dangerous drug» as «any drug or substance which is for the time being comprised in the First Schedule», section 39B(1) prohibits trafficking in «a dangerous drug», whether on your own behalf or on behalf of any other person, and section 39B(2) sets the penalty. And the word «trafficking» is itself defined in section 2, far wider than selling: it «includes the doing of any of the following acts, that is to say, manufacturing, importing, exporting, keeping, concealing, buying, selling, giving, receiving, storing, administering, transporting, carrying, sending, delivering, procuring, supplying or distributing any dangerous drug otherwise than under the authority of this Act or the regulations made under the Act». Keeping, carrying and storing are on that list, so nothing commercial has to be shown. None of them carries a section 37(da) presumption weight, and none is in the fourteen-substance amphetamine block that subparagraph (xxv) aggregates. So there is no presumption to rebut and no threshold to stay under, and section 39B(2) applies in the same terms as it would to a weighed substance. The other presumption is still there. Section 37(d) provides that any person found to have had in his custody or under his control anything whatsoever containing a dangerous drug «shall, until the contrary is proved, be deemed to have been in possession of such drug and shall, until the contrary is proved, be deemed to have known the nature of such drug». The words «until the contrary is proved» put the defendant to proof on both limbs, on the possession and on the knowledge. Death is available and it is no longer mandatory, and the change has a date. Section 39B(2) once read simply «on conviction with death». The Dangerous Drugs (Amendment) Act 2017, Act A1558, in force 15 March 2018, opened a narrow gate out of that, a date carried forward from the earlier reading and not re-derived in this pass. The Abolition of Mandatory Death Penalty Act 2023, Act 846, came into operation on 4 July 2023, and section 54 of it is the whole of what it did to the Dangerous Drugs Act: it substituted «be punished with whipping of not less than twelve strokes» for fifteen strokes in subsection (2), and it deleted subsections (2A) and (2B), which were the mandatory death machinery. Section 39B(2) now reads, in full: «Any person who contravenes any of the provisions of subsection (1) shall be guilty of an offence against this Act and shall be punished on conviction with death or imprisonment for life and shall, if he is not sentenced to death, be punished with whipping of not less than twelve strokes.» So the court chooses between death and imprisonment for life with no precondition, and at least twelve strokes follow any sentence that is not death. Act 846 is widely described as replacing life with a term of thirty to forty years. It did that in the Penal Code, the Firearms (Increased Penalties) Act 1971, the Arms Act 1960, the Kidnapping Act 1961, the Strategic Trade Act 2010 and the Criminal Procedure Code. It did not do it here: the words «imprisonment for life» in section 39B(2) are untouched and no definition of that phrase appears anywhere in the Dangerous Drugs Act, so no year figure is stated in this cell. Section 55 of Act 846 applies the amended section to anyone sentenced after it came into operation even where the offence was committed before. Below trafficking, the possession offence is section 12. Section 11(1) provides that «This Part applies to dangerous drugs listed in Parts III, IV and V of the First Schedule», which is what brings a Part III substance inside Part IV of the Act. Section 12(2) then prohibits having such a drug in your possession, custody or control «unless he is authorized to be in possession, custody or control of such drug or is deemed to be so authorized under this Act or the regulations made thereunder», and section 12(3) punishes a contravention with «a fine not exceeding one hundred thousand ringgit or to imprisonment for a term not exceeding five years or both». Self-administration is section 15(1), at a fine not exceeding five thousand ringgit or imprisonment for a term not exceeding two years, and section 38B(1) then requires supervision for not less than two and not more than three years after the sentence has been served. Three procedural consequences follow automatically. Section 41(1) removes a section 39B charge from the Sessions Court and the Magistrates' Court, so it is tried in the High Court, and section 41A(3) has it tried by a judge sitting alone. Section 41B(1) provides that bail «shall not be granted» where the offence is punishable with death, and also where it is punishable with imprisonment for more than five years. Section 38A, which lets a court deal with a drug dependant under eighteen under the Drug Dependants (Treatment and Rehabilitation) Act 1983 rather than punish him, is expressly unavailable for a section 39B offence. Section 39C separately escalates a repeat offender under the consumption and possession provisions to not less than five and not more than seven years with not more than three strokes. For a compound that Part III does not name, this cell asserts nothing. A different set of synthetic cannabinoids sits in the Poisons Act 1952 Third Schedule, among them the ones sold as JWH-018, as AM-2201, as XLR-11, as MDMB-CHMICA, as 5F-APINACA and as 5F-AMB, a fact carried forward from the earlier reading of that Act and not re-derived here; those are psychotropic substances and not dangerous drugs, and section 39B does not reach them. A compound in neither list is, on the text, in neither regime until the Minister acts under section 45A. The list can move under all of this. Section 45A is headed «Power of the Minister to vary First Schedule» and it operates either on a decision of the Commission on Narcotic Drugs or of the United Nations Organization altering the Schedules to the Single Convention, or simply where the Minister «considers it expedient to add a substance to, or remove a substance from, or vary the First Schedule, he may by order make the requisite modifications». An order takes effect on gazetting and there is no notice period. He has used it twice since the text read here, by P.U. (A) 97 gazetted 2 April 2024 and P.U. (A) 416 gazetted 25 November 2025, both carried forward from the earlier reading and neither re-read in this pass. The text read for this cell is the Attorney General's Chambers updated text headed «As at 4 July 2023», and a later order is not ruled out.

If prescribed or medical

There is no prescription route for the synthetic cannabinoids in Malaysia, and this cell states that rather than leaving a reader to infer it. Every prohibition in the Dangerous Drugs Act 1952, and the definition of trafficking in section 2, is qualified by the words «otherwise than under the authority of this Act or the regulations made under the Act», so a lawful holding is one that sits inside an authority granted under the Act. The authority the Act contemplates is a licence or a regulation made under it, and here there is nothing for one to attach to. It is reached at Part III of the First Schedule for some of them and the Poisons Act Third Schedule for others: Malaysia has no generic synthetic cannabinoid clause and no analogue clause anywhere in the Dangerous Drugs Act, so each compound is named or it is not. Neither Act evidences a registered product containing it. The quoted entry is a Third Schedule one, not a First Schedule one, which is the point: JWH-018 is a Poisons Act psychotropic substance while ADB-FUBINACA and 5F-ADB are dangerous drugs. Whether any authority could exist depends on which compound is in the material, and a product sold under a brand name identifies none of them.

Documentation

There is no document to carry, because there is no lawful holding for a document to evidence. This cell says so plainly rather than leave a traveller looking for paperwork that does not exist for the synthetic cannabinoids. The entry that forecloses the question is «Naphtalen-1-yl-(1-pentyl-1H-indol-3-yl)methanone (JWH-018)», reached at Part III of the First Schedule for some of them and the Poisons Act Third Schedule for others. Section 25 of the Dangerous Drugs Act 1952, the traveller provision, turns on a medicinal preparation supplied by or on the prescription of a medical practitioner residing outside Malaysia, so it has nothing to attach to here. It is also confined to Part V of the Act, the external trade Part, and would not answer a possession charge even if it did apply. Getting the paperwork wrong is not a paperwork penalty. Section 37(d) provides that «any person who is found to have had in his custody or under his control anything whatsoever containing any dangerous drug shall, until the contrary is proved, be deemed to have been in possession of such drug and shall, until the contrary is proved, be deemed to have known the nature of such drug», and section 37(da) can then presume trafficking from the weight of the material alone. A foreign prescription, a licence issued in another country, and religious or traditional use are none of them provided for anywhere in the Act. The entry the document has to answer to, in the First Schedule itself, is «N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA, MAB-CHMINACA)» at Part III. If the document does not answer the entry, the charge is section 12(2) of the Dangerous Drugs Act 1952, possession of a dangerous drug without authority, and section 12(3) sets «a fine not exceeding one hundred thousand ringgit or to imprisonment for a term not exceeding five years or both». Section 12(4) adds whipping of not more than three strokes where the person convicted is a public officer employed at a prison, rehabilitation centre, police lock-up or place of detention.

Drug laws and enforcement change and vary within a country. This is not legal advice. Always confirm with Malaysia’s embassy or official drug authority before traveling; penalties can be severe, including imprisonment.